Stockscreener 앱 받기
67.78
2.21%
-1.53
전일 마감가:
$69.31
열려 있는:
$70.02
하루 거래량:
1.17M
Relative Volume:
1.22
시가총액:
$4.63B
수익:
-
순이익/손실:
$-146.66M
주가수익비율:
-24.61
EPS:
-2.7541
순현금흐름:
$-133.21M
1주 성능:
+8.90%
1개월 성능:
-14.20%
6개월 성능:
+81.42%
1년 성능:
+86.93%
1일 변동 폭
$66.79
$71.18
1주일 범위
$60.35
$71.18
52주 변동 폭
$26.20
$84.56
Apogee Therapeutics Inc Stock (APGE) Company Profile
명칭
Apogee Therapeutics Inc
전화
650-394-5230
주소
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
67.78 | 4.74B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-22 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-01-07 | 개시 | Wolfe Research | Peer Perform |
| 2025-12-17 | 개시 | Stephens | Overweight |
| 2025-12-10 | 개시 | Deutsche Bank | Buy |
| 2025-11-03 | 개시 | Craig Hallum | Buy |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-09-25 | 개시 | RBC Capital Mkts | Outperform |
| 2025-07-07 | 재확인 | BTIG Research | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-11-25 | 개시 | Canaccord Genuity | Buy |
| 2024-05-10 | 개시 | BofA Securities | Buy |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | Guggenheim | Buy |
| 2023-08-08 | 개시 | Jefferies | Buy |
| 2023-08-08 | 개시 | Stifel | Buy |
| 2023-08-08 | 개시 | TD Cowen | Outperform |
| 2023-08-08 | 개시 | Wedbush | Outperform |
모두보기
Apogee Therapeutics Inc 주식(APGE)의 최신 뉴스
Michael Thomas Henderson Sells 20,000 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock - MarketBeat
What is Apogee Therapeutics Inc. s 5 year growth outlookPortfolio Value Report & Technical Buy Zone Confirmations - mfd.ru
Aug Volume: What is Apogee Therapeutics Inc. s 5 year growth outlookDip Buying & Safe Entry Point Identification - mfd.ru
What’s the beta of Apogee Therapeutics Inc. stockTrade Volume Report & Technical Pattern Alert System - mfd.ru
Apogee Therapeutics touts quarterly-to-biannual AD dosing shift, expands asthma ambitions at conference - MarketBeat
Page not foundAirwhon - MarketBeat
APGE: Quarterly dosing, rapid itch relief, and strong safety set up a 2029 launch to challenge market leaders - TradingView
Aug Breakouts: Can Apogee Therapeutics Inc. stock outperform in a bear marketJuly 2025 Opening Moves & Daily Volume Surge Trade Alerts - mfd.ru
Candriam S.C.A. Invests $5.01 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Can Apogee Therapeutics Inc. sustain earnings growth2025 Year in Review & Capital Efficient Trade Techniques - mfd.ru
Apogee Therapeutics stock hits 52-week high at 62.24 USD By Investing.com - Investing.com South Africa
Apogee Therapeutics stock hits 52-week high at 62.24 USD - Investing.com
Smart Money: Should I set a stop loss on Lichen International LimitedEarnings Growth Summary & Weekly Top Gainers Alerts - baoquankhu1.vn
Trading the Move, Not the Narrative: (APGE) Edition - Stock Traders Daily
Portfolio Update: What is Apogee Therapeutics Incs 5 year growth outlook2025 Sector Review & Fast Moving Trade Plans - baoquankhu1.vn
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Apogee Therapeutics CMO sells $361,860 in shares By Investing.com - Investing.com Australia
Insider Selling: Apogee Therapeutics (NASDAQ:APGE) Insider Sells 5,500 Shares of Stock - MarketBeat
Insider Sell: Jane Henderson Sells 2,000 Shares of Apogee Therap - GuruFocus
Apogee Therapeutics CMO sells $361,860 in shares - Investing.com
Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns By Investing.com - Investing.com Canada
Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns - Investing.com
What drives Apogee Therapeutics Inc.’s stock priceEarnings Overview Summary & Low Risk Entry Point Tips - mfd.ru
Fairmount Funds Management LLC Increases Stake in Apogee Therape - GuruFocus
Aug Gainers: Can Apogee Therapeutics Inc stock outperform in a bear marketWeekly Stock Recap & Long-Term Growth Stock Strategies - baoquankhu1.vn
Exane Asset Management Invests $2.05 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics, Inc. (APGE) Stock Analysis: Unveiling A 49.24% Upside In Biotech - DirectorsTalk Interviews
Does Apogee Therapeutics Inc. meet Warren Buffett’s criteriaEntry Point & Consistent Return Investment Signals - mfd.ru
(APGE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Aug Shorts: What are TrueBlue Incs growth leversGap Down & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Sanofi (SNY) Phase III Data Sparks Attention in Atopic Dermatitis Space - GuruFocus
Promising Biotech Stocks To ResearchJanuary 24th - MarketBeat
Aug Breakouts: Whats the RSI of Adicet Bio Inc stockPrice Action & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Fairmount Healthcare Fund II L.P. sells Apogee (APGE) shares for $133.53 million By Investing.com - Investing.com Nigeria
Promising Biotech Stocks Worth WatchingJanuary 23rd - MarketBeat
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Apogee Therapeutics (NASDAQ:APGE) Trading Down 10.2% Following Insider Selling - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Director Fairmount Funds Management Llc Sells 1,750,000 Shares - MarketBeat
Fairmount Healthcare Fund II L.P. sells Apogee (APGE) shares for $133.53 million - Investing.com
Apogee Therapeutics stock downgraded by RBC Capital on valuation concerns By Investing.com - Investing.com Nigeria
Apogee Therapeutics stock downgraded by RBC Capital on valuation concerns - Investing.com India
RBC Downgrades Apogee Therapeutics to Sector Perform From Outperform, Raises Price Target to $83 From $70, Keeps Speculative Risk - marketscreener.com
Apogee Therapeutics: 2026 Inflection Point In Immunology (NASDAQ:APGE) - Seeking Alpha
Apogee Therapeutics, Inc. (APGE) Stock Analysis: A Biotech Gem with a 27.70% Upside Potential - DirectorsTalk Interviews
Bear Alert: Whats the beta of Apogee Therapeutics Inc stock2025 Analyst Calls & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics CEO Henderson sells $1.6m in stock By Investing.com - Investing.com Nigeria
Apogee Therapeutics (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 20,000 Shares - MarketBeat
Apogee Therapeutics CEO Henderson sells $1.6m in stock - Investing.com
Price-Driven Insight from (APGE) for Rule-Based Strategy - Stock Traders Daily
Apogee Therapeutics Inc (APGE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):